Please assess the completion status of the following clinical trial:

Trial Title: A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight/obese adult males/females 18-75 years of age with a BMI ≥ 27 kg/m2;~* At least 1 weight-related comorbidity (i.e., hypertension, dyslipidemia, Type 2 diabetes mellitus \[T2DM\] or prediabetes, or obstructive sleep apnea).~* Must be ambulatory, willing, and able to wear ABPM monitor apparatus for 24 hours at beginning and end of study.~Exclusion Criteria:~* Screening blood pressure of \> 140/90 mmHg;~* Type 1 diabetes; T2DM treated with SFUs, GLP-1 receptor agonists, SGLT inhibitors; or not on stable diabetic medications for at least 3 months prior to randomization;~* Clinically significant cardiac, hepatic, renal, pulmonary, or thyroid disease;~* History of bipolar disorder, psychosis, greater than one lifetime episode of major depressive disorder, or presence or history of suicidal behavior or suicidal ideation with intent to act;~* History of glaucoma;~* Night shift workers;~* Obesity of known genetic or endocrine origin; recent history of weight instability, or recent participation in a formal weight loss program within 3 months prior to screening; and~* Smoking cessation within 3 months prior to screening;~* Use of antihypertensive medications, antidiabetic medications, statins or other lipid lowering agents, or CPAP therapy that has not been stable for at least 3 months prior to randomization;~* COVID-19 vaccination or treatment for severe COVID-19 infection within a month prior to randomization.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 Top Dose (Phentermine 15 mg + Topiramate 92 mg) (Type: EXPERIMENTAL): Week 1: VI-0521 (Phentermine 3.75 mg + Topiramate 23 mg) oral capsule, once daily; Week 2: VI-0521 (Phentermine 7.5 mg + Topiramate 46 mg) oral capsule, once daily; Week 3: VI-0521 (Phentermine 11.25 mg + Topiramate 69 mg) oral capsule, once daily; Weeks 4-8: VI-0521 (Phentermine 15 mg + Topiramate 92 mg) oral capsule, once daily
- Phentermine 30mg (Type: ACTIVE_COMPARATOR): Weeks 1-8: Phentermine 30mg oral capsule, once daily
- Placebo (Type: PLACEBO_COMPARATOR): Weeks 1-8: Placebo oral capsule, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).